药物输送
免疫原性
生物制药
靶向给药
微粒
生物制药
药品
计算机科学
纳米技术
药理学
医学
化学
材料科学
工程类
生物技术
抗体
生药学
免疫学
体外
生物活性
生物
生物化学
化学工程
作者
Hao Lou,Mei Feng,Michael J. Hageman
标识
DOI:10.1016/j.xphs.2022.08.036
摘要
Multiple advanced formulations and drug delivery systems (DDSs) have been developed to deliver protein-based biotherapeutics via the subcutaneous (SC) route. These formulations/DDSs include high-concentration solution, co-formulation of two or more proteins, large volume injection, protein cluster/complex, suspension, nanoparticle, microparticle, and hydrogel. These advanced systems provide clinical benefits related to efficacy and safety, but meanwhile, have more complicated formulations and manufacturing processes compared to conventional solution formulations. To develop a fit-for-purpose formulation/DDS for SC delivery, scientists need to consider multiple factors, such as the primary indication, targeted site, immunogenicity, compatibility, biopharmaceutics, patient compliance, etc. Next, they need to develop appropriate formulation (s) and manufacturing processes using the QbD principle and have a control strategy. This paper aims to provide a comprehensive review of advanced formulations/DDSs recently developed for SC delivery of proteins, as well as some knowledge gaps and potential strategies to narrow them through future research.
科研通智能强力驱动
Strongly Powered by AbleSci AI